Based on a preliminary count of the voting results from the meeting of stockholders, more than 88% of the votes cast were voted in favor of Proposal No. 1 to approve the issuance of Sesen Bio common stock to Carisma stockholders in the merger and approximately 86% of votes were cast in favor of Proposal No. 2, representing more than 57% of outstanding shares of Sesen Bio common stock, to approve the amendment to Sesen Bio’s certificate of incorporation to effect a reverse stock split of outstanding shares of Sesen Bio common stock at a ratio of 1-for-20. The approval of Proposal Nos. 1 and 2 was needed to complete the merger. Sesen Bio currently anticipates that the reverse stock split will become effective after trading hours on March 7, 2023, such that trading of post-split Carisma common stock will commence on March 8, 2023. The merger is expected to close on March 7, 2023, subject to customary closing conditions.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SESN:
- Sesen Bio reports Q4 EPS (4c), consensus (11c)
- Sesen Bio announces Glass Lewis recommendation to vote for merger with Carisma
- Sesen Bio boosts special cash dividend to 36c per share, Torok to join board
- Sesen Bio gets Nasdaq delisting notice, company sees Carisma deal as viable path
- Sesen Bio: Pending Carisma merger in best interests of stockholders